Company Overview of Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops therapeutic products for treatment of inflammatory, gastrointestinal, and metabolic diseases. Its product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September, 2008. Ritter Pharmaceuticals, In...
1801 Century Park East
Los Angeles, CA 90067
Founded in 2004
Key Executives for Ritter Pharmaceuticals, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $348.7K
Founder, President and Director
Total Annual Compensation: $259.3K
Co-Founder, Executive Chairman and Chief Strategic Officer
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2015.
Ritter Pharmaceuticals, Inc. Key Developments
Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board
Nov 21 15
Ritter Pharmaceuticals, Inc. announced the appointment of William J. Sandborn, M.D. to its Medical Advisory Board. Dr. Sandborn serves as the Chief, Division of Gastroenterology and Director at University of California San Diego Inflammatory Bowel Disease Center and Professor of Clinical Medicine. From April 1993 to December 2010, Dr. Sandborn was head of the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN and from January 2011 to present, the Division of Gastroenterology, University of California.
Ritter Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter Ended September 30, 2015
Nov 17 15
Ritter Pharmaceuticals, Inc. reported unaudited earnings results for the third quarter ended September 30, 2015. For the third quarter of 2015, the company reported a net loss attributable to common stockholders of approximately $3.1 million compared to a net loss of approximately $0.4 million for the third quarter of 2014. Basic and diluted net loss per share was $0.40 for the compared to basic and diluted net loss per share of $0.92 for the same period in 2014. Operating loss was $3.1 million against $0.3 million a year ago.
Ritter Pharmaceuticals, Inc. Announces Executive Changes
Oct 26 15
Effective November 1, 2015, Samuel Lynn will cease serving as the Chief Financial Officer of Ritter Pharmaceuticals, Inc. Ellen Mochizuki, Vice President, Finance of the Company, will serve as sole principal financial officer. The Company previously reported the hiring of Ms. Mochizuki effective September 18, 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 18, 2015